We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds
News

Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds

Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds
News

Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. has announced that it has entered into a service agreement with CombinatoRx, Incorporated (CombinatoRx).

Using its combination “High Throughput Screening” technology, cHTS™, CombinatoRx has identified synergistic combinations with utility in key indications which TDR will optimize utilizing its expertise in computational and medicinal chemistry and partner ADME services.

Dr. Mark Warne, Managing Director of TDR, stated, “We are delighted to be entering into this new and exciting agreement with CombinatoRx. Following TDR’s recent acquisition by CBI, this agreement serves as further confirmation that we remain focused on providing integrated drug discovery services to the pharmaceutical and biotech community, working closely with our clients throughout the drug discovery process.”

Advertisement